Abundance Wealth Counselors Sells 820 Shares of Gilead Sciences, Inc. $GILD

Abundance Wealth Counselors lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% in the 2nd quarter, Holdings Channel reports. The firm owned 27,335 shares of the biopharmaceutical company’s stock after selling 820 shares during the period. Abundance Wealth Counselors’ holdings in Gilead Sciences were worth $3,018,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences in the 1st quarter valued at about $25,000. Activest Wealth Management lifted its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences in the 1st quarter valued at about $29,000. Colonial Trust Advisors lifted its holdings in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its holdings in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 241 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock worth $9,402,130. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $110.56 on Friday. The company has a market cap of $137.18 billion, a PE ratio of 22.02, a P/E/G ratio of 0.76 and a beta of 0.34. Gilead Sciences, Inc. has a 52-week low of $83.98 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm’s 50 day moving average price is $114.42 and its 200-day moving average price is $109.91.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GILD shares. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Finally, Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.